NNVC

NanoViricides Inc

Add to Watchlist

$

1.710

-0.04(-2.286%)1D

Overview
Forecast
Valuation
Earnings

Line

|

Candle

1D

5D

1M

3M

6M

YTD

1Y

5Y

High

1.770

Open

1.770

VWAP

1.72

Vol

158.87K

Mkt Cap

27.48M

Low

1.660

Amount

273.50K

EV/EBITDA(TTM)

--

Total Shares

11.81M

EV

25.58M

EV/OCF(TTM)

--

P/S(TTM)

--

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

Show More

Valuation Metrics

The current forward P/E ratio for NanoViricides Inc (NNVC.A) is -2.98, compared to its 5-year average forward P/E of -2.71. For a more detailed relative valuation and DCF analysis to assess NanoViricides Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.71

Current PE

-2.98

Overvalued PE

-1.27

Undervalued PE

-4.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

7.72

Undervalued EV/EBITDA

-16.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.35

Current PS

0.00

Overvalued PS

1.41

Undervalued PS

-0.70

Financials

Annual

Quarterly

FY2025Q3

N/A

Total Revenue

FY2025Q3

YoY :

+17.86%

-2.25M

Operating Profit

FY2025Q3

YoY :

+19.54%

-2.22M

Net Income after Tax

FY2025Q3

YoY :

-12.50%

-0.14

EPS - Diluted

FY2025Q3

YoY :

+0.14%

-1.99M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

0

3-6

Months

0.0

Volume

0

6-9

Months

0.0

Volume

0

0-12

Months

0.0

Volume

0

Bought

0-3

0

0.0

Volume

Months

3-6

0

0.0

Volume

Months

6-9

0

0.0

Volume

Months

0-12

0

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

NNVC News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

08:44:58

NanoViricides discusses potential of NV-387 drug

2025-07-21 (ET)

2025-07-21

07:29:34

NanoViricides says achieved success in developing Measles drug

2025-07-16 (ET)

2025-07-16

08:44:47

NanoViricides comments on extension of MPox Public Health Emergency

Sign Up For More Events

Sign Up For More Events

News

9.5

05-15Yahoo Finance

NanoViricides: Fiscal Q3 Earnings Snapshot

9.0

03-07Business Insider

Biotech Alert: Searches spiking for these stocks today

4.0

2024-08-25SeekingAlpha

Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)

Sign Up For More News

People Also Watch

GlycoMimetics Inc

Above Food Ingredients Inc

J-Long Group Ltd

Skillful Craftsman Education Technology Ltd

BioXcel Therapeutics Inc

EQUUS Total Return Inc

Lytus Technologies Holdings Ptv Ltd

Glen Burnie Bancorp

FAQ

What is NanoViricides Inc (NNVC) stock price today?

The current price of NNVC is 1.71 USD — it has decreased -2.29 % in the last trading day.

What is NanoViricides Inc (NNVC)'s business?

What is the price predicton of NNVC Stock?

What is NanoViricides Inc (NNVC)'s revenue for the last quarter?

What is NanoViricides Inc (NNVC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for NanoViricides Inc (NNVC)'s fundamentals?

How many employees does NanoViricides Inc (NNVC). have?

What is NanoViricides Inc (NNVC) market cap?